TBZ depletes vesicular stores of dopamine by inhibiting the vesicular monoamine transporter 2 (VMAT‐2) and is another effective drug for the treatment of dystonia as well as other hyperkinetic MD, such as chorea, tics, tardive dyskinesia, and myoclonus (Kenney et al., 2007). The gene discussed is SLC18A2; the disease is Dystonia.